Analysis of non-steroidal anti-inflammatory drug use in hospitalized patients and perception of their risk

Interdisciplinary Toxicology

Volumn 6, Issue 3, 2013, Pages 141-144

  Varga, Zoltán ^a   Kriška, Milan ^a   Kristová, Viera ^a   Petrová, Miriam ^a  

^a Bratislava   (Slovakia)

Author keywords

adverse effect; cardiovascular risk; non steroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; DICLOFENAC; DIPYRONE; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DRUG USE; FEMALE; HEART FAILURE; HEART INJURY; HOSPITAL PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY INJURY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MIDDLE AGED; PATIENT INFORMATION; PERCEPTION; PHARMACIST; PHYSICIAN; QUESTIONNAIRE; STOMACH INJURY; THROMBOSIS;

EID: 84897928171     PISSN: 13376853     EISSN: 13379569     Source Type: Journal    
DOI: 10.2478/intox-2013-0022     Document Type: Article

References (14)

1. Adams RJ, Appleton SL, Gill TK, Taylor AW, Wilson DH, Hill CL. (2011). Cause for concern in the use of non-steroidal anti-inflammatory medications in the community-a population-based study. BMC Family Practice 12: 70.
2. Arellano F, Sacristan JA. (1990). Metamizole: reassessment of its therapeutic role. Eur J Clin Pharmacol 38(6): 617-619. (Pubitemid 20206038)
3. Bresalier RS, Sandler RS, Quan H. (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New Engl J Med 352(11): 1092-1102. (Pubitemid 40365350)
4. Cannon PJ. (1986). Prostaglandins in congestive heart failure and the effects of nonsteroidal anti-inflammatory drugs. Am J Med 81: 123-32. (Pubitemid 16006988)
5. Cullen G, Kelly E, Murray FE. (2006). Patientś knowledge of adverse reactions to current medications. Br J Clin Pharmacol 62(2): 232-236. (Pubitemid 44316433)
6. Douthwaite AH. (1938). Recent advances in medical diagnosis and treatment. Brit Med J 1: 1143-1146.
7. Hudec R, Kriska M, Bozekova L, Foltan V. (2008). Comparison of NSAID consumption in Slovakia, Finland and Norway. Bratisl Lek Listy 109(8): 370-373.
8. Johnson AG, Nguyen TV, Day RO. (1994). Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 121(4): 289-300.
9. Lanas AI. (2001). Current approaches to reducing gastrointestinal toxicity of low-dose aspirin. Am J Med 110(1A): 70S-73S. (Pubitemid 32144909)
10. McGettigan P, Henry D. (2011). Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 8(9): e1001098.
11. Mukherjee D. (2002). Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol 63(5): 817-821. (Pubitemid 34242993)
12. Staessen J, Fagard R, Lijnen P, Moerman E, De Schaepdryver A, Amery A. (1983). Effects of prostaglandin synthesis inhibition on blood pressure and humoral factors in exercising, sodium-deplete normal man. J Hypertens 1: 123-30. (Pubitemid 14191608)
13. Trelle S, Reichenbach S, Wandel S et al. (2011). Cardiovascular safety of nonsteroidal anti-inflammatory drugs: network meta-analysis. Brit Med J 342: c7086.
14. Walshe JJ, Venuto RC. (1979). Acute oliguric renal failure induced by indomethacin: possible mechanism. Ann Intern Med 91: 47-49. (Pubitemid 9229601)